Unknown

Dataset Information

0

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.

ABSTRACT: Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete response (CR) rates and may improve overall survival (OS) for patients with

SUBMITTER: Landau H 

PROVIDER: S-EPMC5220129 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.

Landau H H   Smith M M   Landry C C   Chou J F JF   Devlin S M SM   Hassoun H H   Bello C C   Giralt S S   Comenzo R L RL  

Leukemia 20160818 1

Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete response (CR) rates and may improve overall survival (OS) for patients with <CR. We retrospectively analyzed outcomes for 143 patients who underwent RA-SCT with or without consolidation. Melphalan was  ...[more]

Similar Datasets

Unknown Multidisciplinary supportive care in systemic light chain amyloidosis.
| S-EPMC9242830 | biostudies-literature
Unknown Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.
| S-EPMC8436337 | biostudies-literature
Unknown Structure and energetic basis of overrepresented ? light chain in systemic light chain amyloidosis patients.
| S-EPMC5927852 | biostudies-literature
Unknown Dysphagia unveiling systemic immunoglobulin light-chain amyloidosis with multiple myeloma.
| S-EPMC6202992 | biostudies-literature
Unknown Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.
| S-EPMC2200859 | biostudies-literature
Unknown Light Chain Amyloidosis.
| S-EPMC5841939 | biostudies-literature
Unknown Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
| S-EPMC4930380 | biostudies-literature
Unknown Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.
| S-EPMC6815750 | biostudies-literature
Unknown Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
| S-EPMC3640126 | biostudies-literature
Unknown Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.
| S-EPMC2964067 | biostudies-literature